Dr. Reddy’s Laboratories Share Price, Stock Analysis & Company Profile
Dr. Reddy’s Laboratories Limited is one of India’s leading pharmaceutical companies with a strong global presence across generics, APIs, and specialty medicines. As a key player in the healthcare and pharma export ecosystem, it has built a reputation for innovation, regulatory compliance, and cost-efficient manufacturing. This page serves as a comprehensive hub for investors seeking an in-depth Dr. Reddy’s Laboratories stock analysis, offering all the essential tools to track the Dr. Reddy’s share price and evaluate its long-term growth potential.
About Dr. Reddy’s Laboratories
Founded in 1984 by Dr. Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It has grown from a domestic API manufacturer into a global pharmaceutical major with operations spanning the US, Europe, Russia, and emerging markets.
Dr. Reddy’s Laboratories focuses on improving access to affordable medicines while maintaining high standards of quality and compliance. The company has a strong presence in regulated markets like the US, where it benefits from a steady pipeline of generic drug launches and complex formulations.
Dr. Reddy’s Laboratories Business Model
The business model of Dr. Reddy’s Laboratories is built on vertical integration, global distribution, and a diversified product portfolio across multiple therapeutic segments. It operates through the following core segments:
Global Generics: This is the largest revenue contributor, covering finished dosage formulations sold across the US, India, Russia, and other international markets. It includes complex generics and branded generics.
Pharmaceutical Services and Active Ingredients (PSAI): This segment focuses on manufacturing and supplying APIs and intermediates to global pharma companies, ensuring backward integration and cost efficiency.
Proprietary Products & Biosimilars: The company invests in innovation through specialty drugs and biosimilars, targeting niche therapeutic areas with high growth potential.
Branded Generics (India & Emerging Markets): A strong domestic presence with branded formulations across key therapies such as gastroenterology, cardiovascular, and oncology.
Contract Development and Manufacturing Services (CDMO): Offers end-to-end services including drug development, manufacturing, and supply chain solutions for global pharma partners.
Dr. Reddy’s Laboratories IPO and Listing Details
Dr. Reddy’s Laboratories has a long-standing presence in the Indian capital markets and is also listed internationally, making it one of the early Indian pharma companies to gain global investor attention.
IPO Listing Year: 1986
IPO Price: Rs 10 per share
Listing Price: The stock debuted with strong investor interest on Indian exchanges.
Face Value: Rs 1 per share
ISIN: INE089A01023
Listing Exchanges: BSE and NSE
BSE Scrip Code: 500124
NSE Symbol: DRREDDY
Dr. Reddy’s Laboratories Corporate Action History
Dr. Reddy’s Laboratories has consistently rewarded its shareholders through dividends and occasional corporate actions, reflecting its stable cash flows and mature business model.
Stock Split History
The company has undertaken stock splits in the past to improve liquidity and make the stock more accessible to retail investors.
2005: Stock Split from a Face Value of Rs 5 to Rs 1
Ex-Date: 10 October 2005
Bonus Share History
The company has also issued bonus shares to enhance shareholder value over time.
2006: 1:1 Bonus Issue (1 bonus share for every 1 share held)
Ex-Date: 20 September 2006
Investor Note: Dr. Reddy’s Laboratories has maintained a balanced capital allocation approach, combining reinvestment in R&D with consistent shareholder rewards through dividends and periodic corporate actions.
Investor Resources Available on This Page
We aim to empower investors with actionable insights and institutional-grade data. On this page, you can access a wide range of tools to conduct your own Dr. Reddy’s Laboratories stock analysis:
Price Chart: Analyse historical price movements and trends to understand the Dr. Reddy’s share price trajectory across market cycles.
Company Ratios: Evaluate key financial metrics such as PE ratio, ROE, ROCE, EBITDA margins, and R&D intensity.
Quarterly Results & Balance Sheet: Track revenue growth, US generics performance, margin trends, and profitability indicators.
Cash Flow & Annual Reports: Examine operational efficiency, capital expenditure, and long-term financial health through official filings.
Shareholding Pattern: Review promoter holdings, institutional ownership (FII/DII), and changes in investor composition.
Pros & Cons: Get a concise breakdown of strengths such as global diversification and regulatory approvals, along with risks like USFDA observations and pricing pressure in generics.
Frequently Asked Questions
Q1. What is the Dr. Reddy’s Laboratories share price today?
The share price displayed at the top of this page reflects the latest trading value on the NSE and BSE. Please note that the price data may be delayed by 15 minutes.
Q2. What does Dr. Reddy’s Laboratories do?
Dr. Reddy’s Laboratories is a global pharmaceutical company engaged in manufacturing generics, APIs, biosimilars, and specialty medicines across multiple markets.
Q3. What was the IPO price of Dr. Reddy’s Laboratories?
The IPO was issued at a price of Rs 10 per share in 1986.
Q4. Has Dr. Reddy’s Laboratories issued bonus shares?
Yes, the company issued bonus shares in a 1:1 ratio in September 2006.
Q5. Where are Dr. Reddy’s Laboratories shares listed?
The shares are listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
Q6. What is the current face value of Dr. Reddy’s Laboratories shares?
Following the stock split in 2005, the face value of each equity share is Rs 1.
Q7. How can I access the Dr. Reddy’s Laboratories Annual Report?
You can download the latest Annual Reports and investor presentations from the “Reports” or “Documents” section available on this page.